December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

2.365 -0.075 (-3.07%)
Streaming Delayed Price Updated: 12:07 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Pricing of Public Offering of Securities
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Proposed Public Offering of Securities
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
From Cellares
Via Business Wire
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
From Cabaletta Bio
Via GlobeNewswire
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
From Cabaletta Bio
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.